News | July 20, 2021
Balaxi Pharmaceuticals Q1 revenue increases by 12%
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
SteriScience will infuse an additional amount of Rs. 74.5 crore, making a total investment commitment of Rs. 114.5 crore in BSL
The first batch will be shipped to the Gamaleya Center for the quality control
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Subscribe To Our Newsletter & Stay Updated
